Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01558817
Other study ID # PilotCPR001
Secondary ID
Status Completed
Phase N/A
First received February 21, 2012
Last updated July 23, 2014
Start date February 2012
Est. completion date April 2014

Study information

Verified date July 2014
Source University of Vermont
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

Outcomes after in-hospital cardiopulmonary resuscitation (CPR) are very poor, particularly in patients with oxygen dependent chronic obstructive pulmonary disease (COPD) or metastatic cancer. Recent work found that in-hospital CPR is being performed more often before death with unchanging survival and that fewer CPR survivors are being discharged home, thus suggesting that CPR is increasingly performed without benefit and that the burden of this ineffective treatment is increasing. Unlike other medical procedures, CPR has become the default provided to all patients even those with tremendously poor outcomes. It is time to change the paradigm of CPR. Through comparing an innovative "informed assent" approach toward in-hospital CPR (informing patients that their underlying chronic illness makes outcomes of CPR so poor that CPR is not performed while allowing them to disagree) versus usual care in a group of chronically ill patients with reduced life expectancy, the investigators aspire to demonstrate that CPR delivery can be reduced. And in addition that DNR status increases, while preserving patient quality of life and decreasing the burden of this ineffective treatment to both patients and families. If effective, this informed assent intervention has the potential to revolutionize how the investigators discuss CPR with the investigators chronically ill patients.


Recruitment information / eligibility

Status Completed
Enrollment 29
Est. completion date April 2014
Est. primary completion date October 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- 18 years or older

- Oxygen dependent COPD or Advanced Malignancy

- Life expectancy of less than two years

Exclusion Criteria:

- Subjects who have already firmly decided to undergo CPR

- Subjects enrolled in a hospice program

- Subjects unable to speak English

- Subjects incapable of making their own decisions at the time of enrollment

- Subjects cared for by the study investigator

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label


Related Conditions & MeSH terms


Intervention

Behavioral:
Informed Assent
Patients receive informed assent approach toward in-hospital CPR outcomes. Patients are informed that their underlying chronic illness makes outcomes after CPR so poor that CPR is not performed while allowing them to disagree.
Informational Brochure
An informational brochure about CPR will be given without a discussion with a physician.

Locations

Country Name City State
United States University of Vermont and Fletcher Allen Health Care Burlington Vermont
United States Medical University of South Carolina Charleston South Carolina
United States University of Washington Seattle Washington

Sponsors (1)

Lead Sponsor Collaborator
University of Vermont

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cardiopulmonary Resuscitation Preference The primary outcome will be the difference in the proportion of patients in the informed assent intervention and informational brochure groups reporting preferences to be DNR (do not rescusitate). Within couple of hours before the intervention and immediately (up to 2 days) after the intervention No
Secondary Depression Patients' and family members' symptomes of depression will be measured by the PHQ-8 questionnaire. Baseline (day of intervention) and 2 weeks after intervention No
Secondary Anxiety Patients and families will complete the GAD-7 questionnaire, a measure of generalized anxiety disorder. Baseline (day of intervention) and two weeks after intervention No
Secondary Physician Order for Life Sustaining Treatment (POLST) Participants who expressed a preference to be DNR will be asked to complete a POLST form by their physician. It will also be explained that this can be changed any time the status changes. Baseline (day of intervention) and 2 weeks after intervention No
Secondary DNR status preference The difference in DNR status preference between patients in the control and invervention group at two weeks after the intervention. Two weeks after the intervention No
Secondary Report on acceptability of the informed assent approach The following questions will be asked:
How helpful was this approach to discussing CPR with respect to CPR decisions?
Would you recommend this approach to discussing CPR for other patients who have serious illnesses?
Within couple of hours (up to 2 weeks) after intervention No
Secondary Assessment of DNR status change or intervention follow-up from primary physician Contact the physician for each patient at 3 months after the study visit to determine whether there are changes in the DNR status or if the physician has talked with the patients about the status since the study visit. Three months after the intervention No
Secondary Resource utilization Record resource utilization for participants that includes hospitalizations, ICU care, use of hospice etc by medical record review. Up to 6 months after intervention or until death No
See also
  Status Clinical Trial Phase
Completed NCT00978926 - A Study of the Pharmacodynamic Effects of Anti-Vascular Endothelial Growth Factor Therapy in Patients With Advanced Malignancies N/A
Completed NCT01444404 - A Study of AMG 820 in Subjects With Advanced Solid Tumors Phase 1
Completed NCT00428545 - Bevacizumab and Bortezomib in Patients With Advanced Malignancy Phase 1
Completed NCT02743637 - A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors Phase 1
Completed NCT01253707 - A Study of AMG 337 in Subjects With Advanced Solid Tumors Phase 1
Completed NCT01723020 - A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma Phase 1
Completed NCT00813384 - A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors Phase 1
Completed NCT00974896 - QUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid Tumors Phase 1
Completed NCT02110355 - A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma Phase 1
Completed NCT02978482 - A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced Malignancies Phase 1
Completed NCT00858377 - A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors Phase 1
Completed NCT04216082 - A Study of Anlotinib in Subjects With Advanced Malignancy Phase 2
Terminated NCT02437916 - Safety Study of AMG 228 to Treat Solid Tumors Phase 1
Terminated NCT01231347 - QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas Phase 3
No longer available NCT01945164 - XL999 Administered Intravenously to a Subject With Advanced Malignancies N/A
Completed NCT03875157 - Study of IBI318 in Participants With Advanced Malignancies Phase 1
Completed NCT02016729 - A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia Phase 1